Cantor Fitzgerald Reiterates Neutral on TherapeuticsMD, Maintains $5 Price Target
BenzingaAug 17, 2023 11:48 ET
TherapeuticsMD Analyst Ratings
BenzingaAug 17, 2023 11:47 ET
TherapeuticsMD Analyst Ratings
Benzinga Analyst RatingsJan 11, 2023 07:47 ET
Cantor Fitzgerald Reinstates Neutral on TherapeuticsMD, Announces $5 Price Target
Benzinga Real-time NewsJan 11, 2023 07:47 ET
HC Wainwright Rating & Price Target On TherapeuticsMD Under Review On 'Unclear Path'
Benzinga Real-time NewsJul 15, 2022 13:36 ET
TherapeuticsMD Price Target Announced at $1.00/Share by Cantor Fitzgerald
Dow JonesJul 13, 2022 08:30 ET
TherapeuticsMD analyst ratings
Benzinga Analyst RatingsJul 13, 2022 08:20 ET
Cantor Fitzgerald Reiterates Neutral on TherapeuticsMD, Announces $1 Price Target
Benzinga Real-time NewsJul 13, 2022 08:20 ET
TherapeuticsMD Cut to Neutral From Buy by HC Wainwright & Co.
Dow JonesJun 7, 2022 07:33 ET
TherapeuticsMD Price Target Announced at $10.00/Share by HC Wainwright & Co.
Dow JonesJun 7, 2022 07:33 ET
TherapeuticsMD analyst ratings
Benzinga Analyst RatingsJun 7, 2022 07:24 ET
HC Wainwright & Co. Downgrades TherapeuticsMD to Neutral, Announces $10 Price Target
Benzinga Real-time NewsJun 7, 2022 07:24 ET
No Data
No Data